Dr. Gemma Vilahur, from the Research Group on Molecular and Therapeutic Pathology of Atherothrombotic and Ischemic Diseases of the São Paulo Research Institute, explained the project “Intravenous administration of a modified HMG-CoA reductase inhibitor as a promising cardioprotective strategy in ischemic heart disease: Unlocking its cardioprotective benefits and mechanisms of action, in a highly transferable pre-clinical animal model”, funded by the Marathon, to a group of interested citizens.
